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Abstract: Large-cell neuroendocrine carcinoma (LCNEC) is a relatively uncommon variant of 
non-small cell lung cancer. Since the biological characteristics of LCNEC are similar to those 
of small cell lung cancer, LCNEC is usually treated with chemotherapy regimens used for small 
cell lung cancer. However, the outcomes are usually dismal. Here, we report a patient with 
LCNEC (a metastasis to the brain). After whole brain irradiation, he received a combination of 
amrubicin and irinotecan chemotherapy, and has been relapse-free for two years. This treatment 
regimen may be beneficial for patients with advanced LCNEC.
Keywords: large-cell neuroendocrine carcinoma, chemotherapy, amrubicin, irinotecan, lung 
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Introduction
Large-cell neuroendocrine carcinoma of the lung (LCNEC) was first proposed 
by Travis and colleagues1 in 1991 as a separate fourth category of pulmonary 
neuroendocrine tumors, in addition to typical carcinoid tumor, atypical carcinoid 
tumor and small-cell lung cancer. The incidence of LCNEC is very low, and appears 
to be between 2.1% and 3.5%.2 The clinical outcome of LCNEC is reported to be 
poorer than that of stage-comparable conventional non-small-cell lung cancer.3,4 
LCNEC belongs, together with small-cell lung cancer, to a group of high-grade 
malignancies, and the prognosis of patients with LCNEC falls between that of 
patients with atypical carcinoid tumor and those with small-cell lung cancer.1 
Little information on chemotherapy for advanced LCNEC exists, and a standard 
treatment strategy for advanced LCNEC is far from being established.5–8 Here, we 
report a patient with stage IV LCNEC who achieved a complete response after 
undergoing whole brain irradiation followed by a combination of amrubicin and 
irinotecan chemotherapy.
Case report
In February 2007, a 66-year-old male patient was transferred to the Kitasato University 
Hospital after an annual check-up chest X-ray revealed a nodule in the right lower 
field of his lung. The patient denied having fever, weight loss, or hemoptysis. 
He had smoked 2.5 packs of cigarettes a day for 40 years. His medical and social 
histories were unremarkable. On physical examination, no significant abnormalities 
were found. The results of routine laboratory studies, including a complete blood 
count, platelet, and blood chemistry screening, were normal, including the tumor Drug Design, Development and Therapy 2009:3 214
Ryuge et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
marker levels (carcinoembrionic antigen, neuron-specific 
enolase, and pro-gastrin-releasing peptide). A computed 
tomography (CT) of the lung confirmed a nodule in the right 
lower lobe with no signs of mediastinal lymphadenopathy 
(Figure 1A). Metastatic multiple tiny pulmonary nodules 
were not observed.
Soon after his first visit, he started to complain of rapidly 
developing dysarthria, right hemiparesis, and gait disturbance. 
A solitary metastasis with a midline shift (2.6 cm in diameter) 
was identified on a brain CT examination (Figure 2A). 
Since we could not rule out the diagnosis of small cell lung 
cancer which has a high propensity for early micrometastases, 
whole-brain irradiation was first given in March 2007, with a 
total dose of 50 Gy delivered in 25 fractions; this treatment 
resulted in a marked symptomatic and a good radiological 
partial response (Figure 2B).
Figure 1 computed tomography image of the chest showing a solitary nodule measuring 
26 mm in diameter in the right lower lobe (A: May 2007) and the complete response to 
four cycles of a combination of amrubicin and irinotecan (B: January 2009).
Figure 2 computed tomography image of the brain showing the brain metastasis 
before treatment (A: March 2007), the good response to whole brain irradiation 
(B: May 2007), and the complete resolution of the brain disease (C: January 2009).Drug Design, Development and Therapy 2009:3 215
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A fiberoptic bronchoscopy was carried out, but a 
diagnosis could not be confirmed. A CT-guided percutaneous 
needle biopsy of the tumor was subsequently performed. 
Histologically, tumor cells were arranged in nests or 
trabeculae, and infiltrated in the fibrous stroma. Individual 
tumor cells were polygonal in shape with relatively abundant 
cytoplasm and vesicular nucleus. Coagulative tumor necrosis 
was also observed (Figure 3A). Immunohistochemistry 
showed positive staining for CD 56, protein-gene product 
9.5 (PGP 9.5) and neuron-specific enolase (NSE) (Figure 3B). 
Thus, the tumor was diagnosed as LCNEC. Additional 
examinations, including bone scanning and an upper 
abdominal CT, showed no signs of abnormalities. Therefore, 
the patient was staged as having T1N0M1. He discontinued 
smoking at the time of his diagnosis.
After whole-brain irradiation, the patient was treated at 
three-week intervals with 25 mg/m2 of amrubicin (5-min 
intravenous injection on days 1–3) plus 60 mg/m2 of CPT-11 
(90-min intravenous infusion on days 1 and 8) starting 
in May 2007. The selection of this regimen was based 
on our previous phase I trial.9 Out of 11 patients entered 
onto the trial, five partial responses were obtained. One 
good partial response was observed only in a patient with 
neuroendocrine properties who had huge liver metastases. 
He received four cycles of this chemotherapy, ending in 
mid-August 2007, and a chest X-ray showed that the primary 
lesion had rapidly decreased in size from 2.5 cm × 2.6 cm 
to 1.4 cm × 0.7 cm within two weeks. A further follow-up 
CT examination showed the complete resolution of both the 
primary lesion and the brain metastasis, and the patient’s 
quality of life was improved (Figures 1B, 2C). As of   
March 1, 2009, he has been progression-free from disease 
for a total of 24 months.
Discussion
Because of the difficulty in making an immunohistochemical 
diagnosis using small specimens, LCNEC is often difficult 
to diagnose correctly using small specimens obtained by 
bronchoscopy or fine needle biopsy.10 Although LCNEC is 
categorized as a variant of large-cell carcinoma,11 LCNEC 
exhibits features of a high-grade neuroendocrine tumor, 
and the biological behavior of LCNEC tumors resembles 
that of small cell lung carcinomas. LCNEC has a worse 
prognosis than stage-equivalent NSCLC.2 Specimens 
obtained using fiber-optic bronchoscopy or percutaneous fine 
needle aspiration should be carefully examined because the 
accurate differentiation of LCNEC from the more common 
large cell lung cancer is important for identifying patients 
with a dismal prognosis. Rossi and colleagues7 reported 
that platinum-doublet chemotherapy regimens that are 
generally recommended for NSCLC, including cisplatin 
plus gemcitabine, were relatively ineffective and that the 
use of standard chemotherapy regimens for SCLC seemed 
to be the most important survival-related variable. Iyoda 
and colleagues12 described a survival benefit in patients with 
surgically resected stage I LCNEC who underwent a standard 
adjuvant chemotherapy regimen typically used for SCLC 
patients. Kozuki and colleagues6 also stated in their study 
of 12 LCNEC patients that combination therapy of cisplatin 
plus etoposide was useful for improving outcome. In a 
retrospective analysis, Yamazaki and colleagues8 reported 
a 50% response rate to cisplatin-based chemotherapy in 
Figure 3 Histologic and immunohistochemical analysis of the tumor specimen obtained during a computed tomography-guided percutaneous tumor biopsy. A: individual 
tumor cells were polygonal in shape with relatively abundant cytoplasm and vesicular nucleus, and were arranged in nests with area of coagulative necrosis. B: Tumor cells Drug Design, Development and Therapy 2009:3 216
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20 LCNEC patients. Fujiwara and colleagues5 suggested that 
a regimen comprised of a platinum-doublet combined with 
irinotecan (CPT-11) or paclitaxel might be active against 
LCNEC. All these authors recommended that LCNECs 
should be treated in a manner similar to that used for 
small cell lung cancer, given their similarity in chemosensi-
tivity and aggressive characteristics, even though LCNECs 
are classified as non-small cell lung cancer. Amrubicin is a 
totally synthetic anthracycline anticancer agent that acts as 
a potent topoisomerase II inhibitor. Amrubicin is converted 
to an active metabolite, amrubicinol.13 The response rates 
to amrubicin in patients with non-small cell lung cancer 
and small cell lung cancer were 25% and 52%–79%, 
respectively.14–16 CPT-11 is a water-soluble camptothecin 
derivative that inhibits topoisomerase I. CPT-11 has shown 
a significant antitumor activity against various human 
malignancies including non-small cell lung cancer and 
small cell lung cancer.17–20 DNA topoisomerase I and II are 
functionally related and are known to act in concert. Since 
the combined use of topoisomerase I and II inhibitors is 
theoretically attractive because of the complementary func-
tions of their targets,21 we previously conducted a phase I 
study of amrubicin combined with CPT-11 for the treatment 
of advanced non-small cell lung cancer.9 During this trial, 
one good PR was obtained in a patient with LCNEC. Similar 
to this previous experience, the present case also showed a 
marked response to the nonplatinum doublet of amrubicin 
and CPT-11, with a progression-free survival period of 
24 months. To our knowledge, this is the first report describ-
ing the use of a nonplatinum doublet for advanced LCNEC. 
Since the combination of cisplatin and etoposide has been 
used extensively for the treatment of this disease, our case 
report adds to the medical literature on the use of amrubicin 
and CPT-11 regimens for the treatment of this increasingly 
recognized malignancy, which has a dismal prognosis and a 
high and early propensity to metastasize. However, Rossi and 
colleagues7 reported the median diameter of their LCNEC 
tumors was 40 mm. Our tumor size was 26 mm. The small 
tumor volume may have good influence on the response to the 
combination regimen of amrubicin and CPT-11. However, 
it is difficult to make valid conclusions about the ultimate 
clinical activity of this combination regimen on the basis 
of this case report. Therefore, phase II/III trials are needed 
to allow a precise estimate of the degree of activity of this 
regimen against advanced LCNEC.
In conclusion, the combination of amrubicin and 
CPT-11 is a promising and well-tolerated regimen based 
on its unique mechanisms of action and may be a novel 
therapeutic approach capable of improving the survival 
rates of patients with LCNEC, a very rare but aggressive 
neuroendocrine tumor.
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